by Suman Gupta
-
ABPL’s quality systems, traceability, zero observation by regulators and GLP certification catapults its credibility and fast track growth
-
Biologics worth USD 100 billion in sales will go off-patent by 2020 making Asia Pacific one-third contributor of bio-similar market